Efficacy of Infliximab comparing with Cyclophosphamide in refractory uveitis in Behcet’s diseases

Study of the Efficacy of Infliximab in comparison with Cyclophosphamide in refractory uveitis in Behcet’s diseases

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180110038297N1

Enrollment

Registered

2018-05-02

Start date

2017-03-21

Completion date

Unknown

Last updated

2018-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory uveitis in patients with Behcet. Behcet's disease

Interventions

Intervention 1: Intervention group: The 10-membered group receiving infliximab by intravenous injection at a dose of 3 mg / kg in weeks 0, 2, 6 and then 8 weeks later (a total of four injections) with

Eligibility

Sex/Gender

All

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Behcet’s disease Refractory uveitis Retinal vesiculitis

Exclusion criteria

Exclusion criteria: Patient dissatisfaction Contraindications for administration of Infliximab or cyclophosphamide Non response to medication

Design outcomes

Primary

Measure	Time frame
Total Inflammatory Activity Index. Timepoint: Measuring the total inflammatory activity index at the beginning of the study (prior to the intervention) and 2, 6 and 8 weeks after starting Infliximab, as well as measuring the index at the beginning of the study (before the intervention) and 1, 2 and 3 months later Start taking Endoxan. Method of measurement: Total inflammatory activity index is defined as right eye ([AU ×1] + [PU ×2] + [RV ×3]) + left eye ([AU ×1]+[PU ×2] + [RV ×3]) in which the PU stands for Posterior Uveitis, AU denotes Anterior Uveitis and RV shows Retinal Vasculitis.;Total Adjusted Disease Activity Index. Timepoint: Measuring the total inflammatory activity index at the beginning of the study (prior to the intervention) and 2, 6 and 8 weeks after starting Infliximab, as well as measuring the index at the beginning of the study (before the intervention) and 1, 2 and 3 months later Start taking Endoxan. Method of measurement: Total Adjusted Disease Activity Index is defined as TIAI + right eye ([VA-10] ×2) + left eye ([VA-10] ×2) in which TIAI stands for Total inflammatory activity index and VA is the visual acuity.	—

Measure

Time frame

Total Inflammatory Activity Index. Timepoint: Measuring the total inflammatory activity index at the beginning of the study (prior to the intervention) and 2, 6 and 8 weeks after starting Infliximab, as well as measuring the index at the beginning of the study (before the intervention) and 1, 2 and 3 months later Start taking Endoxan. Method of measurement: Total inflammatory activity index is defined as right eye ([AU ×1] + [PU ×2] + [RV ×3]) + left eye ([AU ×1]+[PU ×2] + [RV ×3]) in which the PU stands for Posterior Uveitis, AU denotes Anterior Uveitis and RV shows Retinal Vasculitis.;Total Adjusted Disease Activity Index. Timepoint: Measuring the total inflammatory activity index at the beginning of the study (prior to the intervention) and 2, 6 and 8 weeks after starting Infliximab, as well as measuring the index at the beginning of the study (before the intervention) and 1, 2 and 3 months later Start taking Endoxan. Method of measurement: Total Adjusted Disease Activity Index is defined as TIAI + right eye ([VA-10] ×2) + left eye ([VA-10] ×2) in which TIAI stands for Total inflammatory activity index and VA is the visual acuity.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzadeh Behnam Ghader

Zanjan University of Medical Sciences

abehnamghader@zums.ac.ir+98 24 3377 0801

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026